TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02670707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine/prednisone
Description: Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day
Study: NCT04612660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on cervical cancer prevetnion
Description: Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic group interaction
Description: Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician engagement
Description: Engaging community bilingual physicians in cervical cancer screening and referral;
Study: NCT02745795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional Interview
Description: Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
Study: NCT01812395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy using harmonic focus (r)
Description: Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thyroidectomy
Description: Vessels are ligated with sutures then cut using classic scalpel or scissors.
Study: NCT00399685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
Study: NCT03067337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless Steel Crown (Group A)
Description: Full coverage restoration for multi-surface carious teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuSmile Zirconia Crowns (Group B)
Description: Full coverage restoration for multi-surface carious teeth
Study: NCT02064647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trend Arrow Adjustment Tool
Description: The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10/20% bolus adjustment
Description: The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
Study: NCT04942288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The first group is acupressure and massage, the second group is massage
Description: In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The first group is acupressure and massage, the second group is massage
Description: In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
Study: NCT01524497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 75mg tablet/150 mg tablet
Study: NCT03410940

Intervention type: DEVICE
Intervention: CLS Brevius stem with Kinectiv technology
Study: NCT02982850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT01337947

Intervention type: DRUG
Intervention: Definity microbubbles
Description: Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
Study: NCT03523754

Intervention type: DRUG
Group type: OTHER
Intervention: Isosorbide Mononitrate 40 MG to study group
Description: Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group

Intervention type: DRUG
Group type: OTHER
Intervention: Isosorbide Mononitrate 40 MG to study group
Description: Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
Study: NCT03958799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation B
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation B
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation C
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation C
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study: NCT04612660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
Study: NCT03958799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation A
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation A
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation D
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tdap vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tdap vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study: NCT02766062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolic syndrome
Description: metabolic syndrome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolic syndrome
Description: metabolic syndrome
Study: NCT04612660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
Study: NCT01356342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S 2010-2011, inactivated
Description: The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S 2010-2011, inactivated
Description: The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S 2010-2011, inactivated
Description: The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections
Study: NCT01065948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous glucose monitoring device
Description: monitor interstitial glucose level every 5 min over 4 hours
Study: NCT03190265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
Study: NCT03196635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Assisted (PA) Breast Compression
Description: The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technologist-Controlled (TC) Breast Compression
Description: TC compression will be conducted per standard of care practices at the site.
Study: NCT01953978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
Study: NCT01071005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorelin Depot Bergamo
Description: Lorelin Depot Bergamo, 3,75 mg, single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot - Abbott
Description: Lupron Depot 3,75 mg, single dose.
Study: NCT00182767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study: NCT03663530

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meal times
Description: Meal times vary based on the arm: aligned or misaligned
Study: NCT02618174

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Control Condition
Description: Message about age of University of Birmingham

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Food-based Control Condition
Description: Message about variety of vegetables in the world

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Condition
Description: Message about the health benefits of eating vegetables

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Descriptive Social Norm
Description: Message suggesting most people eat plenty of vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liking Social Norm
Description: Message suggesting most people like eating vegetables
Study: NCT03472469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV/PO
Description: Acetaminophen 1g IV/PO every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen PO
Description: Acetaminophen 1g PO every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen PO
Description: Acetaminophen 1g PO every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg IV once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg IV once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Celebrex 200mg PO every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg PO every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg PO every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg PO every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 100mg PO every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300mg PO every 8 hours
Study: NCT01524497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
Study: NCT04373772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage
Description: the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
Study: NCT01953978

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study: NCT00124124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH; Peptides; Dendritic Cells
Description: Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH, peptides plus Montanide
Description: Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
Study: NCT01862484

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Restricted Diet
Description: Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Ruse Diet
Description: Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
Study: NCT03037437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (SOR)
Description: Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (SOR)
Description: Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: 400mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: 400mg by mouth daily
Study: NCT00805961

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
Study: NCT03663530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal times
Description: Meal times vary based on the arm: aligned or misaligned
Study: NCT04140955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tapering plan and telephone counselling
Description: Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
Study: NCT01659281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 6 mg/kg/day for 2 days (total dose 12 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 4 mg/kg/day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: 15mg/kg at T=0 and 10 mg/kg 6-24 hours later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: 8 mg/kg daily for 3 days
Study: NCT00747344

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Controlled Period (CP)
Description: Placebo, Weeks 0-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg - CP
Description: Ustekinumab 45 mg, Weeks 0-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ustekinumab 45 mg - after CP
Description: Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg - after CP
Description: Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
Study: NCT00989235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV solution, IV, 10 mg/Kg, Once monthly, 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV solution, IV, 5 mg/Kg, Once monthly, 1 year